GPER‐induced signaling is essential for the survival of breast cancer stem cells

Yu‐Tzu Chan, Alan Chuan‐Ying Lai, Ruey‐Jen Lin, Yahui Wang, Yi‐Ting Wang, Wen‐Wei Chang, Hsin‐Yi Wu, Yu‐Ju Lin, Wen‐Ying Chang, Jen‐Chine Wu,

International Journal of Cancer · 2019 · 53 citations · 34 references

DOIFull text

Open access

Concepts

Abstract

G protein‐coupled estrogen receptor‐1 (GPER), a member of the G protein‐coupled receptor (GPCR) superfamily, mediates estrogen‐induced proliferation of normal and malignant breast epithelial cells. However, its role in breast cancer stem cells (BCSCs) remains unclear. Here we showed greater expression of GPER in BCSCs than non‐BCSCs of three patient‐derived xenografts of ER − /PR + breast cancers. GPER silencing reduced stemness features of BCSCs as reflected by reduced mammosphere forming capacity in vitro , and tumor growth in vivo with decreased BCSC populations. Comparative phosphoproteomics revealed greater GPER‐mediated PKA/BAD signaling in BCSCs. Activation of GPER by its ligands, including tamoxifen (TMX), induced phosphorylation of PKA and BAD‐Ser118 to sustain BCSC characteristics. Transfection with a dominant‐negative mutant BAD (Ser118Ala) led to reduced cell survival. Taken together, GPER and its downstream signaling play a key role in maintaining the stemness of BCSCs, suggesting that GPER is a potential therapeutic target for eradicating BCSCs.

References

34